Valeant Pharmaceuticals Intl Inc Declines A lot Today, Is Now One of The Worst Performer

 Valeant Pharmaceuticals Intl Inc Declines A lot Today, Is Now One of The Worst Performer

The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) is a huge mover today! About 1.66 million shares traded hands or 55.14% up from the average. Valeant Pharmaceuticals Intl Inc (TSE:VRX) has declined 29.58% since April 1, 2016 and is downtrending. It has underperformed by 31.53% the S&P500.
The move comes after 8 months negative chart setup for the $6.84B company. It was reported on Nov, 8 by Barchart.com. We have $19.21 PT which if reached, will make TSE:VRX worth $342.00 million less.

Valeant Pharmaceuticals Intl Inc (TSE:VRX) Ratings Coverage

Out of 2 analysts covering Valeant Pharmaceuticals International (TSE:VRX), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. $74 is the highest target while $38 is the lowest. The $42.50 average target is 110.19% above today’s ($20.22) stock price. Valeant Pharmaceuticals International has been the topic of 14 analyst reports since October 20, 2015 according to StockzIntelligence Inc. On Tuesday, January 26 the stock rating was maintained by RBC Capital Markets with “Outperform”. The company was maintained on Friday, June 3 by RBC Capital Markets. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, September 20. The firm has “Sector Perform” rating given on Wednesday, September 7 by RBC Capital Markets. As per Monday, June 20, the company rating was maintained by RBC Capital Markets. The rating was maintained by RBC Capital Markets on Monday, June 27 with “Sector Perform”. The stock has “Hold” rating given by TD Securities on Wednesday, July 20. The rating was maintained by RBC Capital Markets with “Sector Perform” on Tuesday, October 11. The stock of Valeant Pharmaceuticals Intl Inc (TSE:VRX) earned “Sector Perform” rating by RBC Capital Markets on Tuesday, October 25. The firm earned “Outperform” rating on Tuesday, October 20 by RBC Capital Markets.

More notable recent Valeant Pharmaceuticals Intl Inc (TSE:VRX) news were published by: Fool.com which released: “Why Valeant Pharmaceuticals Intl Inc Stock Is Slumping Today” on November 08, 2016, also Fool.com with their article: “Another Month, Another 27% Decline for Valeant Pharmaceuticals Intl. Inc. in …” published on November 07, 2016, Profitconfidential.com published: “Valeant Pharmaceuticals Intl Inc: Did VRX Stock Just Bottom?” on November 03, 2016. More interesting news about Valeant Pharmaceuticals Intl Inc (TSE:VRX) were released by: Fool.com and their article: “3 Figures in Focus When Valeant Pharmaceuticals Intl. Inc. Reports Its Q3 Results” published on November 01, 2016 as well as Schaeffersresearch.com‘s news article titled: “Buzz Stocks: CVS Health Corp, Valeant Pharmaceuticals Intl Inc, and Facebook Inc” with publication date: November 08, 2016.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has a market cap of $6.84 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

VRX.TO Company Profile

Valeant Pharmaceuticals International, Inc., incorporated on August 9, 2013, is a specialty pharmaceutical and medical device company. The Firm is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Firm operates through two divisions: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal (GI) disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses primarily on branded generics, OTC products and medical devices.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment